Article Figures & Data
Figures
- FIGURE 1.
Kaplan–Meier OS of 24 prostate cancer patients at WVU hospital from time of first 223Ra isotope infusion.
Tables
Characteristic ALSYMPCA WVU Patients (n) 614 24 Median survival (mo) 14.9 8.3 (P = 0.01) Median age (y) 71 (range, 49–90) 68 (range, 54–89) >75 y old (n) 171 (28%) 4 (17%) Caucasian (n) 575 (94%) 24 (100%) Current bisphosphonates (n) Yes 250 (41%) 15 (63%) No 364 (59%) 9 (37%) Prior docetaxel (n) Yes 352 (57%) 17 (71%) No 262 (43%) 7 (29%) ECOG performance status (n) 0 165 (27%) 1 (4%) 1 371 (60%) 14 (58%) 2+ 77 (13%) 9 (38%) WHO ladder for cancer pain (n) 0 3 (13%) 1 257 (42%) 3 (13%) 2 151 (25%) 7 (29%) 3 194 (32%) 11 (46%) ECOG = Eastern Cooperative Oncology Group; WHO = World Health Organization.
Parameter ALSYMPCA (614 patients) WVU (23 patients) Total alkaline phosphatase <220 U/L 348 (57%) 18/23 (78%) >220 U/L 266 (43%) 5/23 (22%) Hemoglobin (g/dL) 12.2 (8.5–15.7) 11.5 (8.6–15.3) Albumin (g/L) 40 (24–53) 33.5 (17–39) Total alkaline phosphatase (U/L) 211 (32–6431) 115 (68–820) Lactate dehydrogenase (U/L) 315 (76–2171) 274 (118–809) Prostate-specific antigen (μm/L) 146 (3.8–6026) 75.4 (1.5–928) Data are median followed by percentage or range.
Parameter ALSYMPCA WVU Bone metastases (n) 100 (16%) 3/23 (13%) 6–20 262 (43%) 5/23 (22%) >20 195 (32%) 14/23 (61%) Superscan 54 (9%) 1/23 (4%) Radiation < 12 wk from screening Yes 99 (16%) 3 (13%) No 515 (84%) 21 (87%)
Jump to section
Related Articles
Cited By...
- No citing articles found.